Targeting Insomnia to Help Prevent Relapse in Adults Recovering from Alcohol Use Disorder – UROP Spring Symposium 2023

Targeting Insomnia to Help Prevent Relapse in Adults Recovering from Alcohol Use Disorder

Huiyi Lin

Huiyi Lin photo

Pronouns: she/her

Research Mentor(s): J Todd Arnedt
Research Mentor School/College/Department: Psychiatry / Medicine
Program: UROPF
Session: Session 6 (3:40pm – 4:30pm)
Authors:

Abstract

Alcohol Use Disorder (AUD) is a leading cause of morbidity and mortality in the United States (Mokhad et.al., 2004) and, despite there being many existing treatment options, 70-80% of people will relapse within 12 months of receiving treatment (Stilman et.al., 2020). Insomnia has been demonstrated to be an independent predictor of relapse (Brower, 2015), making it a promising intervention target to help prevent relapse. The Michigan Sleep Treatment to Avoid Relapse (MSTAR) study is a randomized controlled trial investigating insomnia as a potential intervention target for preventing relapse in adults in early recovery from AUD. Participants are recruited from AUD treatment programs and the community via social media advertising and are screened to confirm eligibility based on whether they fit the probable Diagnostic and Statistical Manual of Mental Disorders-5 criteria for AUD and insomnia. Once enrolled, participants are randomized to 6 sessions of one of two treatments delivered via telemedicine: Cognitive Behavioral Therapy (CBTi-TM) or a Sleep Health Education (SHE-TM) control condition. The primary outcomes of this study are the percent days abstinent measured via the Timeline Follow-Back (TLFB) assessment, insomnia severity measured via the Insomnia Severity Index (ISI), and daytime symptoms of insomnia, measured by the Multidimensional Fatigue Inventory (MFI). Assessments are completed at baseline, then at one week, three months, six months, and twelve months following completion of the intervention. We hypothesize that participants who receive CBTi-TM will demonstrate a higher percentage of days abstinent and greater improvements in insomnia and daytime symptoms than participants who receive SHE-TM. Our results could lead us to recognize insomnia as a treatment target for AUD and gain more insightful information on the relationship between alcohol and insomnia.

Life Science

lsa logoum logo